StockData
IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Immix Biopharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$8.22+0.24 (+3.01%)

Close on Oct 19, 2026

Market cap
$524.20M
P/E (TTM)
–
Dividend yield
–

Immix Biopharma, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Immix Biopharma does not break out revenue by segment, region or product in the tagged data of its filings for this period type.